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Abstract Overexpression of inducible nitric oxide synthase
causes the production of high levels of nitric oxide, which, under
pathological conditions, leads to immunosuppression and tissue
damage. The results recently obtained using peptide nucleic
acids, rather than traditional oligonucleotides as antigen and
antisense molecules, prompted us to test their efficacy in the
regulation of nitric oxide production, thereby overcoming the
obstacle of cellular internalization. The cellular permeability of
four inducible nitric oxide synthase antisense peptide nucleic
acids of different lengths was evaluated. These peptide nucleic
acids were covalently linked to a hydrophobic peptide moiety to
increase internalization and to a tyrosine to allow selective 125I
radiolabelling. Internalization experiments showed a 3^25-fold
increase in the membrane permeability of the modified peptide
nucleic acids with respect to controls. inducible nitric oxide
synthase inhibition experiments on intact stimulated macro-
phages RAW 264.7 after passive permeation of the two antisense
peptide nucleic acids 3 and 4 demonstrated a significant decrease
(43^44%) in protein enzymatic activity with respect to the
controls. These data offer a basis for developing a good
alternative to conventional drugs directed against inducible nitric
oxide synthase overexpression.
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1. Introduction
Nitric oxide (NO) is an important vascular and neuronal
messenger and a cytotoxic agent produced by three di¡erent
isoforms of NO synthase, eNOS, nNOS and inducible NOS
(iNOS) [1^3]. The ¢rst two forms are constitutively expressed
while iNOS was ¢rst described in macrophages and is ex-
pressed as a consequence of various in£ammatory stimuli
[4]. Under these circumstances, NO mediates anti-microbial
and anti-tumoral activities of the immune system, but long-
term NO overproduction causes tissue damage and other seri-
ous diseases [1^4]. These two opposite e¡ects imply that the
organism must regulate NO synthesis precisely. Pharmacolog-
ical research has developed many synthetic inhibitors able to
modulate the production of NO in pathological conditions [4].
The main problems concern the aspeci¢c activity of the enzy-
matic inhibitors that can negatively interact with all three
isoforms of NOS and often interfere with other unrelated
metabolic cellular pathways [2]. Thus, selective blockade of
iNOS activity is a major goal and the use of an antisense
strategy to achieve this result would overcome the undesired
side-e¡ects of conventional inhibitors.
Recently, various studies have demonstrated that speci¢c
oligonucleotide analogs are able to permeate cell membranes
through endocytosis and to some degree to inhibit iNOS [5,6].
In the last years, the partial inhibition of iNOS using a speci¢c
antisense oligonucleotide in an ‘in vivo’ shock model has also
been described [7].
In this study, a di¡erent approach to the antisense strategy
was used, by means of experiments involving internalization
and inhibition of translation by a novel class of oligonucleo-
tide analogs named peptide nucleic acids (PNA). In these
molecules, the entire deoxyribose phosphate moiety is re-
placed by an uncharged pseudo-peptide backbone consisting
of N-(2-aminoethyl)glycine units linked to the purine and pyr-
imidine bases of natural nucleic acids [8]. These structures
form very stable complexes with complementary DNA or
RNA and are resistant to enzymatic degradation in biological
£uids and tissues [8^12]. We have previously described the
synthesis and characterization of a speci¢c PNA able to in-
hibit the translation of iNOS in a cell-free model [13]. In the
present study, we have addressed the design and synthesis of
modi¢ed iNOS-directed antisense PNA molecules to be used
in intact cells and modi¢ed accordingly. Stimulated RAW
264.7 murine macrophages were investigated with respect to
their susceptibility to these PNA molecules and to other
PNAs designed as negative controls.
2. Materials and methods
2.1. PNA designing and synthesis
Three antisense PNAs of di¡erent lengths (Table 1), 5 (PNA 1), 10
(PNA 2) and 14 (PNA 3) bases, respectively, complementary to the
homopurinic regions 238^242, 238^247, 238^251 of the iNOS mouse
cDNA (accession number M84373), were synthesized and chemically
modi¢ed by the introduction of a hydrophobic peptide moiety at the
carboxy-terminal to increase the membrane permeability [14] and of a
tyrosine at the amino-terminal to allow selective radiolabelling with
125I.
Three control molecules lacking the hydrophobic moiety (PNA 1a,
2a, 3a) were synthesized as well (Table 1). A scrambled PNA (PNA
3c) of 14 bases with the hydrophobic portion was obtained and used
as negative control to evaluate the selective antisense activity of PNA
3 in intact cell cultures. Two other PNAs, the ¢rst with an antisense
sequence identical to PNA 3 (PNA 4) and the second with a
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scrambled sequence identical to PNA 3c (PNA 4c) (Table 1), as neg-
ative control, were synthesized with a hydrophobic peptide moiety of
four rather than of six amino acids. The PNA-chimera (1, 2, 3, 3c, 4,
4c) and the control molecules (1a, 2a, 3a) were manually synthesized
using the standard method of solid phase peptide synthesis which
follows the tert-butoxycarbonyl (Boc) strategy [15,16] with minor
modi¢cations [14]. Brie£y, 25 Wmol of 4-methyl-benzhydril-amine-
polystyrene (MBHA-PS)-Phe-Boc deprotected resin (Novabiochem
AG, Laufel¢ngen, Switzerland) in the case of PNA-chimera, or alter-
natively, of MBHA-PS-Gly-Boc deprotected resin for control PNAs,
was treated for 20 min at 40‡C with a coupling reaction mixture
containing ¢ve equivalents (eq) of the appropriate Boc-amino acid
(Novabiochem) or Boc-PNA monomer (Perseptive Biosystems,
PRIMM, Milan, Italy), 4.5 eq of o-(7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexa£uorophosphate (PRIMM), ¢ve eq of N,N-
diisopropilethylamine (Fluka Chemie AG, Buchs, Switzerland), 7.5 eq
of Sim-Collidine (Fluka) at 0.1 M monomer (or amino acid) ¢nal
concentration in anhydrous N-methyl pyrrolidone (Fluka). All the
synthesized compounds were puri¢ed by reverse phase high perform-
ance liquid chromatography (RP-HPLC) and their molecular weights
¢nally con¢rmed by electrospray mass spectrometry (ESMS) (see Sec-
tion 2.6 below).
2.2. Iodination of PNAs
PNAs 1, 1a, 2, 2a, 3, 3a and 4 were radioactively labelled with 125I
on the amino-terminal tyrosine following the method described in
[17]. All PNAs employed in the following experiments had a speci¢c
activity of 0.35 WCi/nmol.
2.3. Cell cultures
All experiments were performed on the mouse macrophage cell line
RAW 264.7 (obtained from the American Type Culture Collection
Rockville, MD, USA) cultured in DMEM containing 4 mM gluta-
mine supplemented with 10% FCS [13]. Cell stimulation to promote
iNOS synthesis in intact murine macrophages was achieved by adding
1 ng/ml lipopolysaccharide (LPS) (Sigma, Milan, Italy) to the cell
cultures 18 h before processing cells to obtain lysates in which the
iNOS enzymatic activity was evaluated.
2.4. Internalization and metabolism of PNAs in RAW 264.7 cells
PNAs 1, 1a, 2, 2a, 3, 3a and 4, labelled with 125I and with a speci¢c
activity of 0.35 WCi/nmol, were incubated at a ¢nal concentration of
1 WM for each PNA with a RAW 264.7 cell culture. Brie£y, exponen-
tially growing cells (106/ml) were treated with each PNA for 6, 12, 24 h
(or 12, 24, 78 h with PNA 4) at 37‡C and 6% CO2. After incubation,
cells were extensively washed with ice-cold PBS, resuspended in
300 mM sucrose and 10 mM Tris-HCl, pH 6.5, (lysis bu¡er) at a
dilution of 2.5U106 cells/ml and sonicated to disrupt cell membranes.
Aliquots were withdrawn to evaluate the total cellular radioactivity in
a Packard Q-counter, then, samples were ultracentrifuged on a TL-100
Beckman for 15 min at 100 000Ug, the membrane pellet was resus-
pended in lysis bu¡er (the same volume as the supernatant) and the
radioactivity was measured in the Q-counter. In addition, incubations
of 24 h with 1 mM PNA 4 were carried out at 37‡C using a RAW
264.7 cell lysate (obtained by ¢ve cycles of freezing at 380‡C for
30 min and thawing at 37‡C for 10 min). In a parallel incubation,
intact cultured RAW 264.7 (106 cell/ml) were treated for 72 h with
1 WM PNA 4 (125I speci¢c activity of 0.35 WCi/nmol). At 2, 6, 24 h,
aliquots of the lysate, or after 72 h, samples of intact cells, were
withdrawn (the cells washed with ice-cold PBS) and extracted with
one volume of methanol added to lysate or intact cells resuspended in
PBS.
PNA 4 and its metabolites in lysate extracts were analyzed by RP-
HPLC directly coupled to ESMS as described previously [14]. The
metabolites of the same compound present in the cell culture extracts
were separated by RP-HPLC (see Section 2.6) and during analysis,
fractions of 0.5 ml were collected for radioactivity evaluation in a
Q-counter. Identi¢cation of metabolites in the cell culture incubation
was performed by comparing the retention time of each HPLC peak
with HPLC-ESMS patterns of the lysates in which each metabolite
peak occurring in the HPLC chromatogram was assigned a mass via
ESMS analysis directly coupled to the HPLC.
2.5. NOS assay
The protein concentration was analyzed using the standard method
of Bradford [18]. The NOS assay was performed by evaluating the
conversion of [3H]arginine to [3H]citrulline in cell lysates. Exponen-
tially growing RAW 264.7 cells were cultured in 25 cm2 £asks for
4 days with 1 WM PNA 3 or 4 and its corresponding controls, PNA
3c or 4c, or alternatively for 7 days with 1 WM PNA 4 and 4c. In all
cases, stimulation of RAW 264.7 cells with 1 ng/ml LPS was per-
formed 18 h before processing cells to obtain the cytosolic fraction.
Brie£y, cells were collected and extensively washed with ice-cold PBS,
then, resuspended in 300 Wl 15 mM HEPES, pH 7.5 and lysed by
freezing-thawing (see Section 2.4). An enzymatic assay of cytosolic
glucose-6-phosphate-dehydrogenase was performed on each sample
to con¢rm the disruption of cell membranes and showing similar
activities in treated and untreated cells (data not shown). The lysates
were then centrifuged at 100 000Ug for 20 min, the cytosolic fractions
collected and 200 Wl aliquots were incubated for 1 h at 37‡C with
5 mM EDTA, 0.5 mM NADPH, 60 WM BH4, 1 mM dithiothreitol,
1 mM MgCl2 and 0.1 mM L-arginine, 2 mCi [2,3,4-3H]L-arginine
monohydrochloride (45^70 Ci/mmol, NEN Life Science Products,
Boston, MA, USA) [19]. Lysate proteins were then precipitated by
addition of 5.5% (¢nal concentration) TCA to the incubation mixture.
Residual TCA was removed by a triple extraction with 20 volumes of
diethyl ether as described [20], samples were diluted with one volume
of 15 mM HEPES, pH 7.5, and ¢nally, 100 Wl aliquots were analyzed
by HPLC.
2.6. Analyses and characterization of products and cellular metabolites
All synthesized compounds were analyzed and puri¢ed by RP-
HPLC. The analysis of the crude synthesis products was performed
using an HP 1090 HPLC equipped with a Waters C18 WBondapack
column (3.9U300 mm), while the puri¢cation of individual com-
pounds was obtained on a Shimadzu LC-9A preparative HPLC
equipped with a Waters C18 WBondapack column (19U300 mm).
The solvent program for both analyses was a gradient starting with
100% solvent A for 5 min, linearly increasing to 60% solvent B in
30 min and up to 100% B in 5 min. Solvent A was 0.1% tri£uoroacetic
acid (TFA) in water and solvent B was 0.1% TFA in acetonitrile. The
diode array detector was set at 260 nm during the analyses. Mass
spectra of each compound were acquired using a single quadrupole
HP Engine 5989-A equipped with an electrospray ion source (ESMS)
and set in the positive ion mode and con¢rmed using a Kompact
MALDI 4 TOF spectrometer (Kratos Analytical, Manchester, UK).
HPLC analyses of the lysate extracts obtained from the NOS assay
incubation mixtures were performed on a reverse phase HP ODS
Hypersil column (100U4.6 mm, 5 Wm particulate size) at a £ow rate
of 0.5 ml/min. Analyses were performed by applying a linear gradient
starting with 100% A and linearly increasing to 100% B in 20 min,
bu¡er A being 25 mM sodium acetate and 15 mM sodium heptane-
sulphonate, pH 4.35, and bu¡er B the same as A with the addition of
30% methanol. This analysis allowed a good peak resolution of argi-
nine, citrulline and ornithine as described [21]. 0.5 ml aliquots of
eluate were collected and the radioactivity was counted in a Packard
liquid scintillator.
3. Results
3.1. Synthesis and characterization of PNAs
Synthesis of the di¡erent PNA sequences had ¢nal yields
ranging between 50% and 60% with a purity of 95^98% after
preparative RP-HPLC puri¢cation of products. In all cases,
the mass spectra of the puri¢ed PNAs showed [M+H] ions
consistent with the molecular weights of the expected mole-
cules.
3.2. Internalization and metabolism in RAW 264.7
All PNAs with di¡erent length antisense sequences targeted
to iNOS mRNA, with or without the hydrophobic peptide
moiety (PNAs 1, 1a, 2, 2a, 3, 3a, 4), were ¢rst tested for their
e⁄cacy on intact RAW 264.7 cells. In these experiments, the
roles of the lipophilic peptide vehicle and of its di¡erent chain
lengths as well as the positive or negative contribution to the
membrane permeability of di¡erent size PNA sequences were
compared in time course experiments. After incubations of the
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iodinated PNAs, the radioactivity in intact cells and in mem-
brane and cytosolic fractions was evaluated as reported in
Table 2 and Fig. 1. Modi¢ed PNAs 1, 2, 3 and 4 showed
much higher internalization values with respect to control
PNAs 1a, 2a and 3a at all incubation times. Speci¢cally, the
rates of internalization, expressed as pmol/106 cells, for con-
trol PNAs 1a, 2a and 3a were found to be 3^25 times lower
with respect to modi¢ed PNAs 1, 2, 3 and 4 in intact cells (see
the ‘T’ column of Table 2). Analysis of the membrane and
cytosolic fractions, indicated by the ‘M’ and ‘C’ columns,
respectively, of Table 2, revealed an asymmetric distribution
of the modi¢ed PNA molecules in cells, while similar values
were found for unmodi¢ed PNAs in the same fractions, as
predicted from the chemical structures of the synthesized mol-
ecules. In particular, the experiments revealed that 5^20% of
the modi¢ed PNAs were in the cytosolic fraction and thus
available for iNOS mRNA complementation and inhibition.
Furthermore, this concentration in the cell cytosol was signi¢-
cantly higher with respect to the controls, as reported in Fig. 1
(see the ‘C’ column in Table 2) that displays the great di¡er-
ence in cytoplasmic internalization of the modi¢ed PNAs 1, 2,
3 upon PNAs 1a, 2a, 3a. Lower values were obtained for
PNA 4, with a maximum rate of internalization in intact cells
after 72 h of 62.5 pmol/106 cells and of 7.7 pmol/106 cells only
in the cytoplasm.
All these data con¢rm the considerable advantage obtained
upon introducing a hydrophobic peptide vehicle covalently
linked to the PNAs over the control molecules. Con¢rmation
of the intracellular stability of the PNA moiety itself and of
the tyrosine linkage positioned at the amino-terminal end was
needed to validate the internalization studies based on the
stable 125I labelling of the molecules. This requirement
prompted us to investigate the metabolism of iodinated
PNA 4 in intact RAW 264.7 cells after 72 h of incubation
at a 1 WM PNA concentration in culture medium. The meta-
bolic pattern of conversion of PNA 4 occurring in intact cells
after a 3 day incubation showed, as already described in [14],
a stepwise removal of each amino acid of the peptide moiety,
probably due to carboxypeptidase activities, generating the
following percentages of molecular species: 7.6% intact
PNA 4 (M) = 4524 (M.W.), 17.8% (M-(Gly-Phe)) = 4322,
23.6% (M-(Gly-Phe-Leu)) = 4209 and 50.9% (M-(Gly-Phe-
Leu-Phe)) = 4062. No evidence of enzymatic cleavage of the
125Ilabelled tyrosine residue covalently linked to the amino-
terminal end and of the PNA moiety itself was observed. This
stability strongly validates the data of cellular uptake of all
PNAs synthesized and tested in this study and expressed as
125I radioactivity incorporated by intact cells and subsequently
in membrane and cytosolic cellular fractions.
3.3. Inhibition of iNOS in RAW 264.7 lysates
RAW 264.7 were incubated for 4 days with PNAs 3, 3c, 4
and 4c and for 7 days with PNA 4 and 4c and stimulated.
NOS activity was then evaluated in the cytosolic fraction. To
preserve the cellular growth and viability, the above-men-
tioned prolonged incubations were performed in DMEM sup-
Fig. 1. Cytosolic levels of di¡erent PNA molecules with or without
the hydrophobic peptide vehicle. Data, expressed as pmol/106 cells,
are taken from the experiment indicated in Table 2. Indicated
S.E.M. are based on triplicate experiments.
Fig. 2. Inhibition of iNOS activity in RAW 264.7 cells by PNA 3
(gray columns) after 4 days of incubation and by PNA 4 (white col-
umns) after 7 days. PNA 3 shows a 44% inhibition (second gray
column), while PNA 4 shows a 43% inhibition (second white col-
umn) compared to controls. S.D. derive from triplicate experiments.
Table 1
Nucleotide sequences of the synthesized PNA molecules
PNA Sequence bp
PNA 1 3P-CONH-Phe-Leu-Phe-Leu-Phe-Leu-CTTTC-Lys-Tyr-NH2-5P 238^242
PNA 1a 3P-CONH2-Gly-CTTTC-Lys-Tyr-NH2-5P 238^242
PNA 2 3P-CONH2-Phe-Leu-Phe-Leu-Phe-Leu-CTTTCTCCTT-Lys-Tyr-NH2-5P 238^247
PNA 2a 3P-CONH2-Gly-CTTTCTCCTT-Lys-Tyr-NH2-5P 238^247
PNA 3 3P-CONH2-Phe-Leu-Phe-Leu-Phe-Leu-CTTTCTCCTTTTCC-Lys-Tyr-NH2-5P 238^251
PNA 3a 3P-CONH2-Gly-CTTTCTCCTTTTCC-Lys-Tyr-NH2-5P 238^251
PNA 3c 3P-CONH2-Phe-Leu-Phe-Leu-Phe-Leu-CTTTTTCCCTCTTC-Lys-Tyr-NH2-5P ^
PNA 4 3P-CONH2-Gly-Phe-Leu-Phe-Leu-CTTTCTCCTTTTCC-Lys-Tyr-NH2-5P 238^251
PNA 4c 3P-CONH2-Phe-Leu-Phe-Leu-CTTTTTCCCTCTTC-Lys-Tyr-NH2-5P ^
Nucleotidic sequences of the synthesized antisense and scrambled PNA molecules complementary to the 5P homopurinic encoding region of
iNOS mouse mRNA.
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plemented with 10% FCS. With reference to this, no signi¢-
cant interactions between PNA and serum proteins have been
reported [12,22], strongly suggesting that all PNA dissolved
in the medium was always available for cellular internaliza-
tion.
After 4 days of incubation with PNA 3 (Fig. 2, gray col-
umns), stimulated cells showed a decrease of 44% of iNOS
activity (second gray column), while PNA 3c did not a¡ect it
at all (third gray column). PNA 4 and PNA 4c showed no
signi¢cant inhibition after 4 days of incubation (data not
shown), while a prolonged incubation for a total period of
7 days again showed (Fig. 2, white columns) a selective inhib-
ition of iNOS by PNA 4 corresponding to a 43% decrease in
enzymatic activity with respect to control stimulated cells (sec-
ond white column) and to PNA 4c (third white column).
4. Discussion
Inducible NOS is the enzyme responsible for the production
of relatively large amounts of NO in macrophages in response
to LPS and cytokine stimulation in general potentiating the
host’s immune defense system [4]. However, a pathological
upregulation of the NO synthesis leads to systemic detrimen-
tal e¡ects and self-destruction since NO cannot be stored or
inactivated by conventional mechanisms after release [1^4].
Therefore, a variety of drugs interfering with the activity of
NOS have been developed but they are often toxic and have a
low speci¢city as they block other enzymes as well [2].
This background prompted us to synthesize, in a previous
work [13], a speci¢c anti-NOS PNA for the ‘in vitro’ evalua-
tion of the sequence-selective inhibition of iNOS mRNA
translation, which suggested the possibility of developing an
alternative pharmacological control on NO overproduction,
based upon an antisense PNA strategy. The homopyrimidinic
PNA sequence proved to be a potent ‘in vitro’ selective inhib-
itor of iNOS synthesis by blocking its mRNA translation, so,
we were encouraged to test the speci¢c antisense e¡ect of this
molecule on intact stimulated macrophages. However, to this
purpose, we had to tackle the obstacle of crossing intact cel-
lular membranes, a problem common to oligonucleotides and
their analogs and to PNAs as well [23,24]. The internalization
study performed on four di¡erent length PNAs (Table 2 and
Fig. 1), covalently linked to a hydrophobic peptide, showed
that the cellular internalization rate was signi¢cantly higher
(3^25 times) with respect to control PNAs lacking the hydro-
phobic moiety (Table 2). Furthermore, this study revealed
that the linkage to a longer lipophilic peptide (PNA 1, 2, 3)
results in a much more rapid internalization with respect to
the shorter hydrophobic moiety (PNA 4).
All these data suggest a simple way of modifying PNAs in
order to achieve high intracellular concentrations of these
molecules. That this condition is an important prerequisite
has been underlined in a recent work [23] where a comparison
of the cellular uptake of di¡erent oligonucleotide analogs was
performed, showing lower internalization rates for unmodi¢ed
PNAs with respect to other antisense molecules such as phos-
phorothioates and alkylamino-phosphodiesters. In our study,
similar, and sometimes higher, cellular uptakes were obtained,
compared to the other oligonucleotide analogs. As a follow-
up, the ability of PNAs 3 and 4 (Fig. 2) to exert a speci¢c
inhibitory e¡ect on iNOS expression within the cytoplasmic
compartment of intact RAW 264.7 cells was evaluated. The
selective antisense e¡ect of the two PNAs was evaluated by
measuring the extent of inhibition of conversion of
[3H]arginine to [3H]citrulline by iNOS in stimulated cell ly-
sates (Fig. 2). These experimental conditions excluded calci-
um-dependent activity (e.g. constitutive NOS isoforms) and
re-shuttling of citrulline to arginine by arginine-succinate syn-
thase (data not shown), an event that has been recently de-
scribed in intact RAW 264.7 cells [25]. The HPLC analysis
allowed for the separation of radioactive species (arginine,
citrulline and ornithine) generated during incubations of the
lysates, performing a much more precise assay compared with
well-known conventional methods based upon cationic ex-
change columns [21]. In this respect, the presence of LPS-
induced arginase activity in macrophages, with the consequent
production of variable amounts of ornithine that may alter
the background of cationic exchange columns, has recently
been described [26].
The results shown in Fig. 2 indicate a 44% iNOS-speci¢c
inhibition for PNA 3 after 4 days of incubation and a 43%
iNOS inhibition for PNA 4 after 7 days of incubation. The
di¡erent times required to obtain the maximum antisense ef-
fect of the two molecules are explained by the di¡erent length
of hydrophobic moieties linked to PNAs 3 and 4 that confer
to the ¢rst molecule a more rapid internalization and, subse-
quently, inhibitory ability.
These encouraging results o¡er a promising new alternative
to conventional drugs directed against macrophagic iNOS
overexpression but also to oligonucleotides [6] and their phos-
phorothioate analogs [5] already tested for their speci¢c anti-
sense e¡ect on this enzyme’s activity. Furthermore, an in vivo
study of septic shock on a rat model [7] also reveals the ad-
vantages of an antisense therapy against iNOS macrophagic
Table 2
PNA internalization values (pmol/106 cells)
Time 6 h 12 h 24 h 72 h
PNA T M C T M C T M C T M C
PNA 4 ^ ^ ^ 22.4 19.9 2.4 17.0 14.7 2.2 62.5 54.7 7.7
PNA 3 87.2 82.0 5.2 74.0 63.0 11.0 98.0 80.0 18.0 ^ ^ ^
PNA 3a 2.8 2.2 0.6 7.2 5.8 1.4 11.6 10.0 1.6 ^ ^ ^
PNA 2 41.2 36.0 5.2 68.2 62.6 5.6 153.4 144.0 9.4 ^ ^ ^
PNA 2a 5.0 4.0 1.0 5.4 3.4 2.0 1.2 0.8 0.4 ^ ^ ^
PNA 1 193.2 184.0 9.2 76.6 63.2 13.4 147.2 147.2 19.2 ^ ^ ^
PNA 1a 7.8 7.0 0.8 25.0 22.0 3.0 7.6 7.6 1.0 ^ ^ ^
PNA internalization values expressed as pmol/106 cells at di¡erent incubation times in a RAW 264.7 cell culture. The ‘T’ column displays the
total cellular internalization values while the ‘M’ and ‘C’ columns show the PNA partition between the lipid (i.e. membrane) and cytosolic frac-
tions of total cellular values, respectively.
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overexpression, showing highly promising results in this area
and indicating the possibility of developing a PNA therapy on
an ‘in vivo’ rat model. This goal could be achieved in several
ways: by introducing suitable modi¢cations enhancing inter-
nalization of antisense PNA, by using antigene PNA linked to
nuclear localization signals or by eventually targeting PNA
speci¢cally to the macrophagic compartment through the cou-
pling to macrophage-membrane permeable signal peptides.
These modi¢cations may in principle generate an ideal drug,
able to selectively exert its highly speci¢c pharmacological
action at the proper site of the protein malfunction, thereby
reducing side-e¡ects and systemic toxicity.
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